Perindopril

Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure^[1][2][3][4]. In Vitro:Perindopril erbumine (1 μM, 24 h) ameliorats gliosis and blunts decrease induced by LPS (HY-D1056) in AT2R expression in Rat astrocytoma cell line (C6) and murine microglial cell line (BV2)^[1].
Perindopril erbumine (1 μM, 24 h) prevents IκBα degradation, NFкB nuclear translocation and STAT3 activation induced by LPS (HY-D1056) in C6 and BV2^[1].
Perindopril erbumine (1 μM, 24 h) ameliorats the imbalance in the release of inflammatory cytokine and blunts the aberrant ROS production and the nitrite release induced by LPS (HY-D1056) in C6 and BV2^[1]. In Vivo:Perindopril erbumine (0.1 mg/kg, Oral gavage, once a day for five consecutive days) prevents LPS-induced neuroinflammation in rats^[1].
Perindopril erbumine (0.42 mg/kg, Oral, once a day for 4 weeks) with Huangqi-Danshen decoction (HDD) (4.7 g/kg, Oral, once a day for 4 weeks) attenuates adenine-induced Chronic kidney disease (CKD) in rats^[2].
Perindopril erbumine (0.4-1.5 mg/kg, Oral, once a day for 4-24 weeks) has a persistent effect on blood pressure in spontaneously hypertensive rats (SHR)^[4].